Cravē Professional Information

MELOONO CRAVĒ PATIENT INFORMATION LEAFLET AND PROFESSIONAL INFORMATION

MELOONO CRAVĒ PATIENT INFORMATION LEAFLET

SCHEDULING STATUS

MELOONO CRAVĒ  (VEGETABLE CAPSULES)

COMPLEMENTARY MEDICINE: WESTERN HERBAL MEDICINE/HEALTH SUPPLEMENT

This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

What is in this leaflet

1. What MELOONO CRAVĒ is and what it is used for
2. What you need to know before you use MELOONO CRAVĒ
3. How to use MELOONO CRAVĒ
4. Possible side effects
5. How to store MELOONO CRAVĒ
6. Contents of the pack and other information.

1. WHAT MELOONO CRAVĒ IS AND WHAT IT IS USED FOR:

• Helps to metabolise carbohydrates, fats and proteins.
• Helps to maintain and / or support cardiovascular health.
• Aids in the muscle recovery process by reducing muscle tissue damage associated with a resistance training regimen.
• Helps support muscle tissue repair in individuals involved in resistance training.
• Helps improve physical performance when used in conjunction with a training regimen.
• Helps delay fatigue during physical activity.
• Contributes to normal red blood cell formation.
• Contributes to the protection of cells from oxidative stress.
• Contributes to tissue formation.
• Is a factor in the maintenance of good health.
• Is an antioxidant for the maintenance of good health.
• Provides support for healthy glucose metabolism.

WHAT YOU NEED TO KNOW BEFORE YOU TAKE CRAVĒ

Do not take CRAVĒ COMPLEX:   

2. WHAT YOU NEED TO KNOW BEFORE YOU USE MELOONO CRAVĒ

Do not use MELOONO CRAVĒ:

• If you are hypersensitive (allergic) to any of the ingredients of MELOONO CRAVĒ.
• Not recommended for children under the age of 18 years.

Warnings and precautions:

Consult your healthcare practitioner prior to use if:

• If you are taking blood pressure medication.
• If you are pregnant or breastfeeding.
• If you have diabetes.
• If you experience symptoms of low blood sugar such as sweating, paleness, chills, headache, dizziness and/or confusion, you should discontinue use and consult a relevant health care provider.

Other medicines and MELOONO CRAVĒ:

• Always tell your health care provider if you are taking any other medicine. (This includes all complementary or traditional medicines).

MELOONO CRAVĒ with food and drink:

• Take capsules with water.

Pregnancy and Breastfeeding:

• The safety of MELOONO CRAVĒ during pregnancy and lactation has not been established.

Driving and using machinery:

• MELOONO CRAVĒ should have no or negligible influence on the ability to drive and use machines.

3. HOW TO TAKE MELOONO CRAVĒ

Always take MELOONO CRAVĒ exactly as directed in this leaflet or as your healthcare provider has told you. You should check with your healthcare provider if you are unsure.

The usual dose is:

• Take three (3) capsules daily. Take 2 – 4 hours prior to exercise.
• Do not exceed recommended daily dose without consulting a relevant healthcare provider.

Paediatric population: Not recommended for children under the age of 18 years.

If you take more MELOONO CRAVĒ than you should:
In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison centre.

If you forget to use MELOONO CRAVĒ:
Do not take more MELOONO CRAVĒ to make up for forgotten use.

4. POSSIBLE SIDE EFFECTS

MELOONO CRAVĒ can have side effects.

Not all side effects reported for MELOONO CRAVĒ are included in this leaflet. Should your general health worsen or if you experience any untoward effects while using MELOONO CRAVĒ, please consult your healthcare provider for advice.

If any of the following happens, stop using MELOONO CRAVĒ and tell your doctor immediately or go to the casualty department at your nearest hospital:

• Swelling of your hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing
• Rash or itching.
• Fainting.

These are all very serious side effects. If you have them, you may have had a serious allergic reaction to MELOONO CRAVĒ. You may need urgent medical attention or hospitalisation.

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

Reporting of side effects

If you get side effects, talk to your doctor or pharmacist. You can also report side effects to SAHPRA via the “6.04 Adverse Drug Reaction Reporting Form”, found online under SAHPRA’s publications: https://www.sahpra.org.za/Publications/Index/8. By reporting side effects, you can help provide more information on the safety of MELOONO CRAVĒ.

5. HOW TO STORE MELOONO CRAVĒ

• Keep all medicines out of the reach of children.
• Store at or below 25 °C.
• Protect from moisture. Keep the container well closed.
• Close the container tightly after opening.
• Do not refrigerate.
• Keep in the original container until ready for use.
• Do not store in a bathroom.
• Do not use after the expiry date stated on the bottle.
• Return all unused medicine to your pharmacist.

Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

Each serving contains 3 capsules

What MELOONO CRAVĒ looks like and contents of the pack

MELOONO CRAVĒ are white capsules filled with light brown powder.

120 Capsules are packed into 250 ml clear PET bottles with 2 g silica sachets and foam inserts closed with smooth white plastic lids. The bottles are sealed with a vent seal.

Holder of Certificate of Registration

Meloono Pty Ltd

info@meloono.co.za

This leaflet was last revised in

June 2025.

The Professional Information is below.

MELOONO CRAVĒ PROFESSIONAL INFORMATION

SCHEDULING STATUS:

1. NAME OF THE MEDICINE:

Meloono Cravē

Strength

Multicomponent

Pharmaceutical form

Vegetable capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION:

Inactive Ingredients:

For full list of excipients, see section 6.1.

Sugar free.

3. PHARMACEUTICAL FORM

MELOONO CRAVĒ capsules are white capsules filled with light brown powder.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

MELOONO CRAVĒ:

• Helps to metabolise carbohydrates, fats and proteins.
• Helps to maintain and / or support cardiovascular health.
• Aids in the muscle recovery process by reducing muscle tissue damage associated with a resistance training regimen.
• Helps support muscle tissue repair in individuals involved in resistance training.
• Helps improve physical performance when used in conjunction with a training regimen.
• Helps delay fatigue during physical activity.
• Contributes to normal red blood cell formation.
• Contributes to the protection of cells from oxidative stress.
• Contributes to tissue formation.
• Is a factor in the maintenance of good health.
• Is an antioxidant for the maintenance of good health.

• Provides support for healthy glucose metabolism.

4.2. Posology and method of administration

Take three (3) capsules daily first thing in the morning before food.

Do not exceed recommended daily dose without consulting a relevant healthcare provider.

Paediatric population: Not recommended for children under the age of 18 years.

4.3. Contraindications

• Hypersensitivity to any of the ingredients.
• Do not use if pregnant or breastfeeding.
• Do not use while taking antibiotics.

Consult a registered healthcare provider prior to use if you are taking any other medicine or have been diagnosed with a chronic condition.

See “4.4 SPECIAL WARNINGS AND PRECAUSTIONS FOR USE”.

4.4. Special warnings and precautions for use

Consult a health care provider prior to use if you are pregnant or breastfeeding.

Consult a health care provider prior to use:

if you have leucopenia, a kidney disorder, hypotension or blood pressure problems, hypoglycemia or diabetes use anti-depressants or blood thinners.

4.5. Interaction with other medicines and other forms of interaction

None known.

4.6. Fertility, pregnancy and lactation

Cravē has not been tested for safe use during Pregnancy and Lactation.

4.7. Effects on ability to drive and use machines

Effects on ability to drive and use machines has not been established.

4.8. Undesirable effects

The frequencies of adverse reactions are ranked according to the following:

• Frequent > 1/100 
• Less frequent < 1/100
• Frequency not known

Immune system disorder

• Frequency not known:
• Allergic reactions (dermatitis, urticaria, skin rash, pruritus, anaphylaxis,
• asthma) may occur.

Gastrointestinal disorder

• Frequency not known:
• Mild gastrointestinal symptoms such as dry mouth, nausea, vomiting,
• upset stomach, abdominal pain, gastric irritation and diarrhoea may occur.

Nervous system disorder

Frequency not known:
Headache

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are requested to report any suspected adverse drug reactions to SAHPRA via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website. 

4.9. Overdose

In overdose, side effects can be precipitated and/or be of increased severity.

Treatment is symptomatic and supportive.

See section “4.8. Undesirable effects.”

5. PHARMACOLOGICAL PROPERTIES

Pharmacological classification

D 34.12 Multiple Substance Formulation.

5.1 Pharmacodynamic properties

Not applicable.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Not applicable.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule shell, microcrystalline cellulose.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months.

6.4 Special precautions for storage

• Store at or below 25 °C.
• Keep the container well closed.
• Protect from moisture and light.
• Close the container tightly after opening.
• Do not refrigerate.

Keep in the original container until ready for use.

6.5 Nature and contents of container

MELOONO CRAVĒ are white capsules filled with light brown powder.

120 Capsules are packed into 250 ml clear PET bottles with 2 g silica sachets and foam inserts closed with smooth white plastic lids. The bottles are sealed with a vent seal.

6.6 Special precautions for disposal and other handling

No special requirements

7. HOLDER OF CERTIFICATE OF REGISTRATION

Meloono Pty Ltd

info@meloono.co.za

REGISTRATION NUMBER

To be allocated